Page 2 - Biocon Ltd News

Biocon gets USFDA's tentative approval for antibacterial drug Rifaximin

The USFDA's tentative approval means Biocon Pharma's Rifaximin 550 mg meets regulatory requirements but cannot be marketed in the US yet due to patents or exclusivity on the original drug

Nifty Pharma down 2.5% as Trump slaps 100% import tariffs; impact decoded

Among individual counters, Sun Pharma slumped 4.87 per cent to a fresh 52-week low of ₹1,548, while Gland Pharma tumbled 4.70 per cent to ₹1,880. Biocon declined 3.68 per cent to ₹342.85.

Biocon share price rises 3% as arm gets USFDA nod for two drugs; details

By 10:35 AM, Biocon share price was trading 2.84 per cent higher at ₹364.45 per share. In comparison, BSE Sensex was trading 0.38 per cent higher at 83,004.53 levels.

Biocon Biologics secures USFDA approval for Bosaya and Aukelso biosimilars

Biocon Biologics gets USFDA approval for Bosaya and Aukelso, denosumab biosimilars of Prolia and Xgeva, with provisional interchangeability status to widen patient access

Stocks to watch today, Sep 11: Bajaj Finserv, DRL, Mazagon, Jupiter Wagons

Stocks to watch on Thursday, September 11: Keystone Realtors, RVNL, Deepak Fertilisers, Torrent Pharma and Adani Ports are among top stocks to track today.

Biocon shares gain 2% after USFDA inspection at Bengaluru facility; details

The inspection covered various aspects of operations including drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses

Biocon shares slip 3% as Q1 results miss estimates; should you sell?

Biocon shares fell 3 per cent after it reported a 95.2 per cent decline in net profit in Q1FY26

Confident about Biocon's response to US tariffs: Kiran Mazumdar-Shaw

We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon Chairperson

Biopharma stock under ₹500 plunges 4%; what should investors do?

The biopharma company's revenue from operations for the quarter ended June 30, 2025, surged 15 per cent year-on-year (Y-o-Y) to ₹3,942 crore, as compared to ₹3,433 crore reported in Q1FY25.

Sensex sinks 600 pts, Nifty near 24,400 amid Trump's tough trade talk

Broader markets witnessed a steeper decline. The Nifty Midcap 100 was trading 0.86 per cent lower, quoting 56,449 levels. Nifty Smallcap, meanwhile, was trading at 17,594, down by 0.56 per cent.

Biocon Q1 results: Net profit down 95%, revenue rises 15% to ₹4,022 cr

Biocon's Q1 net profit declines sharply due to high base from one-time gain last year; biosimilars, CRDMO and generics drive revenue and operational growth

Nifty Pharma down 1.5%: Granules, Biocon lead with over 2% fall; Here's why

Pharma stocks fell after Trump said tariffs will be imposed within a week, rising up to 250 per cent in 12-18 months

Pharma Inc hopes for fair deal as Donald Trump announces 25% tariffs

Trump on Wednesday called India's tariffs on US exports among the highest in the world, with the most strenuous non-monetary trade barriers of any country, in a post on Truth Social

Biocon Biologics appoints Deepali Naair Global Head, Brand & Corp Comm

Biocon Biologics on Wednesday announced the appointment of Deepali Naair as Global Head Brand & Corporate Communications, effective immediately. Deepali will lead the global brand and corporate communications function, responsible for defining and executing an integrated strategy that spans brand positioning, digital presence, regulatory and statutory communications, financial and corporate reporting, media relations, and employer branding, Biocon Biologics, a subsidiary of Biocon Ltd, said in a statement. With over three decades of experience across India, ASEAN, and Australia, Naair brings deep expertise in brand building, marketing, and corporate reputation. In her most recent role as Group Chief Marketing Officer at CKA Birla Group, she was instrumental in shaping the Group's corporate identity, launching new brands, and driving strategic transformations, Biocon Biologics stated. Naair will join the company's Executive Leadership Team (ELT) and report directly to Shreehas ...

Deepali Naair to lead Brand & Corporate Communications at Biocon Biologics

Naair will lead Biocon Biologics' global brand and corporate communications strategy as part of its executive team, reporting directly to CEO and MD Shreehas Tambe

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.

Biocon Biologics expands diabetes portfolio with FDA approval for Kirsty

Interchangeable biosimilar to NovoLog in the US and will be available in prefilled pens and vials

Should you buy Biocon shares as USFDA gives approval to diabetes drug?

At 09:30 AM, Biocon shares were trading at ₹398.15, up by 1.97 per cent on the National Stock Exchange.

Glenmark, Laurus Lab: Will Trump's 200% tariff threat derail pharma stocks?

Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.

Biocon Biologics gets EU nod for two drugs to treat bone diseases

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, expanding its portfolio in bone disease treatment